NYSE:MDT - Medtronic Stock Price, Forecast & News

$119.52

+0.66 (+0.56 %)

(As of 01/17/2020 12:39 PM ET)

Add

Compare

Today's Range

$118.75

Now: $119.52▼

$119.84

50-Day Range

$111.02

MA: $113.96▼

$118.83

52-Week Range

$82.77

Now: $119.52▼

$119.30

Volume2.05 million shs

Average Volume4.05 million shs

Market Capitalization$160.20 billion

P/E Ratio22.90

Dividend Yield1.84%

Beta0.6

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation product; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. Read More…

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Electromedical equipment

Sub-IndustryHealth Care Equipment

SectorMedical

Current SymbolNYSE:MDT

Previous Symbol

CUSIP58505510

CIK1613103

Webhttp://www.medtronic.com/

Phone353-1438-1700

Debt

Debt-to-Equity Ratio0.49

Current Ratio2.77

Quick Ratio2.28

Price-To-Earnings

Trailing P/E Ratio22.90

Forward P/E Ratio21.34

P/E Growth2.84

Sales & Book Value

Annual Sales$30.56 billion

Price / Sales5.24

Cash Flow$7.42 per share

Price / Cash Flow16.10

Book Value$37.44 per share

Price / Book3.19

Profitability

EPS (Most Recent Fiscal Year)$5.22

Net Income$4.63 billion

Net Margins15.11%

Return on Equity14.52%

Return on Assets8.10%

Miscellaneous

Employees90,000

Outstanding Shares1,340,377,000

Market Cap$160.20 billion

Next Earnings Date2/18/2020 (Estimated)

OptionableOptionable

Receive MDT News and Ratings via Email

Sign-up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.

The Stock of the Century - Buy This Stock RIGHT NOW! (Ad)

What if you could buy one tiny stock today for $10 - at the center of a growing tech industry - that experts believe will explode a massive 77,400%?

Wall Street legend Paul Mampilly recently identified this as the stock of the century.

Buying up a handful of shares of this small company now could change your life and even make you millions.

Medtronic (NYSE:MDT) Frequently Asked Questions

What is Medtronic's stock symbol?

Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

How often does Medtronic pay dividends? What is the dividend yield for Medtronic?

Medtronic announced a quarterly dividend on Monday, December 9th. Shareholders of record on Friday, December 27th will be paid a dividend of $0.54 per share on Friday, January 17th. This represents a $2.16 annualized dividend and a yield of 1.81%. The ex-dividend date is Thursday, December 26th. View Medtronic's Dividend History.

How were Medtronic's earnings last quarter?

Medtronic PLC (NYSE:MDT) announced its quarterly earnings results on Tuesday, November, 19th. The medical technology company reported $1.31 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.28 by $0.03. The medical technology company earned $7.71 billion during the quarter, compared to the consensus estimate of $7.66 billion. Medtronic had a return on equity of 14.52% and a net margin of 15.11%. The firm's revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.22 earnings per share. View Medtronic's Earnings History.

When is Medtronic's next earnings date?

Medtronic is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Medtronic.

What guidance has Medtronic issued on next quarter's earnings?

Medtronic updated its FY 2020 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of $$5.57-5.63 for the period, compared to the Thomson Reuters consensus estimate of $$5.56. The company issued revenue guidance of $$31.4-31.7 billion, compared to the consensus revenue estimate of $$31.48 billion.

What price target have analysts set for MDT?

21 analysts have issued 12 month price objectives for Medtronic's stock. Their forecasts range from $99.00 to $135.00. On average, they expect Medtronic's share price to reach $119.90 in the next year. This suggests a possible upside of 0.4% from the stock's current price. View Analyst Price Targets for Medtronic.

What is the consensus analysts' recommendation for Medtronic?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There are currently 4 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medtronic.

What are Wall Street analysts saying about Medtronic stock?

Here are some recent quotes from research analysts about Medtronic stock:

1. Northland Securities analysts commented, "We continue to wait for a definitive breakout in key categories in terms of growth. In fairness, Medtronic continues to improve operational efficiencies." (8/21/2019)
2. Needham & Company LLC analysts commented, "Market open, Ellex announced preliminary FY19 revenue below our expectations and IFRS EBITDA slightly narrower than our expectations. iTrack, 2RT and Tango lasers delivered FY19 y/y revenue growth, but overall growth was below our estimates. Ellex announced the appointment of Maria Maieli, current CFO, as Interim CEO. Ellex expects to release final F2H19 results on August 29, 2019." (7/23/2019)
3. According to Zacks Investment Research, "The declining CRHF segment raises concern for Medtronic. Escalating costs and expenses continue to weigh on Medtronic’s bottom line. On a positve note, in the past year, shares of Medtronic outperformed its industry. The company is successfully registering sustainable growth across major groups and regions, in addition to displaying successful achievement of synergy targets. The company is focusing on geographical diversification of its businesses. This apart, the company has been seeing certain favorable developments in its Diabetes business. The updated 2019 guidance with raised EPS view increases investors’ confidence on the stock. Meanwhile, we are optimistic about the recently-closed acquisition of Mazor Robotics which is expected to fortify Medtronic's position in spine surgery." (5/20/2019)
4. Barclays PLC analysts commented, "We now project $5.15 versus $5.12 consensus. Formal FY20 guidance will come in May but mgmt expressed comfort with the Street EPS estimate (per Refinitiv $5.44) which implies ~5.6% y/y growth off the revised mid- point for FY19. In Jan, mgmt said a higher tax rate could prompt EPS growth to be up to 250bp below its 8% long-range plan (LRP) CAGR target. Mgmt noted it is still working through its options for financial engineering. We think FY20 is likely a back- end loaded year given revenue cadence considerations (i.e. comps, new products launches) as well as FX impacts. We now est. $5.42 vs. $5.38 prior. Net/net, nothing materially changed our view. We think the valuation offers some upside and we rate MDT OW. That said, the upside case may take time to work out as execution confidence builds and many pipeline milestones are more 2020 events." (2/20/2019)

Has Medtronic been receiving favorable news coverage?

Headlines about MDT stock have trended positive on Friday, InfoTrie reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medtronic earned a news impact score of 2.5 on InfoTrie's scale. They also gave news coverage about the medical technology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Medtronic.

Who are some of Medtronic's key competitors?

Some companies that are related to Medtronic include Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

What other stocks do shareholders of Medtronic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medtronic investors own include Johnson & Johnson (JNJ), AT&T (T), Walt Disney (DIS), NVIDIA (NVDA), AbbVie (ABBV), Cisco Systems (CSCO), Home Depot (HD), Starbucks (SBUX), Intel (INTC) and CVS Health (CVS).

Who are Medtronic's key executives?

Medtronic's management team includes the folowing people:

Mr. Omar S. Ishrak, Chairman & CEO (Age 63)
Ms. Karen L. Parkhill, Exec. VP, CFO & Principal Accounting Officer (Age 54)
Mr. Bradley E. Lerman, Sr. VP, Gen. Counsel & Company Sec. (Age 61)
Mr. Michael J. Coyle, Exec. VP and Group Pres of Cardiac & Vascular Group (Age 57)
Mr. Robert J. W. ten Hoedt, Exec. VP and Group Pres, Europe, Middle East & Africa (Age 58)

Who are Medtronic's major shareholders?

Medtronic's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Manning & Napier Group LLC (0.18%), PGGM Investments (0.09%), Hexavest Inc. (0.07%), Calamos Advisors LLC (0.06%), Gateway Investment Advisers LLC (0.04%) and Boston Trust Walden Corp (0.04%). Company insiders that own Medtronic stock include Bradley E Lerman, Carol A Surface, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Karen L Parkhill, Michael J Coyle, Omar Ishrak, Richard H Anderson, Richard Kuntz and Robert John White. View Institutional Ownership Trends for Medtronic.

Which major investors are selling Medtronic stock?

MDT stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Gateway Investment Advisers LLC, Hexavest Inc., State of Alaska Department of Revenue, Calamos Advisors LLC, Community Trust & Investment Co., United Services Automobile Association and Galibier Capital Management Ltd.. Company insiders that have sold Medtronic company stock in the last year include Bradley E Lerman, Carol A Surface, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, Michael J Coyle, Richard Kuntz and Robert John White. View Insider Buying and Selling for Medtronic.

Which major investors are buying Medtronic stock?

MDT stock was purchased by a variety of institutional investors in the last quarter, including PGGM Investments, Johanson Financial Advisors Inc., Centre Asset Management LLC, Central Bank & Trust Co., Sciencast Management LP, Hoey Investments Inc., Webster Bank N. A. and Tuttle Tactical Management. Company insiders that have bought Medtronic stock in the last two years include Karen L Parkhill, Omar Ishrak and Richard H Anderson. View Insider Buying and Selling for Medtronic.

How do I buy shares of Medtronic?

Shares of MDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Medtronic's stock price today?

One share of MDT stock can currently be purchased for approximately $119.37.

How big of a company is Medtronic?

Medtronic has a market capitalization of $160.00 billion and generates $30.56 billion in revenue each year. The medical technology company earns $4.63 billion in net income (profit) each year or $5.22 on an earnings per share basis. Medtronic employs 90,000 workers across the globe.View Additional Information About Medtronic.

What is Medtronic's official website?

The official website for Medtronic is http://www.medtronic.com/.

How can I contact Medtronic?

Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at 353-1438-1700 or via email at [email protected]

MarketBeat Community Rating for Medtronic (NYSE MDT)

Community Ranking:		3.2 out of 5 ( )
Outperform Votes:		1,387 (Vote Outperform)
Underperform Votes:		763 (Vote Underperform)
Total Votes:		2,150

MarketBeat's community ratings are surveys of what our community members think about Medtronic and other stocks. Vote "Outperform" if you believe MDT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDT will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/17/2020 by MarketBeat.com Staff

Your Ultimate Investing Toolkit

Just $1.00 for your first month.